BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 16764744)

  • 1. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
    Dang C; Hudis C
    Clin Breast Cancer; 2006 Apr; 7(1):51-8. PubMed ID: 16764744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
    Hudis C
    Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
    Dang CT
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
    Benson JR
    J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent advances in the hormonal treatment of breast cancer.
    Boughey JC; Buzdar AU; Hunt KK
    Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
    [No Abstract]   [Full Text] [Related]  

  • 6. Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.
    O'Shaughnessy JA; Blum JL
    Clin Breast Cancer; 2006 Apr; 7(1):42-50. PubMed ID: 16764743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
    Nowak AK; Wilcken NR; Stockler MR; Hamilton A; Ghersi D
    Lancet Oncol; 2004 Jun; 5(6):372-80. PubMed ID: 15172358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxanes in the treatment of early breast cancer.
    Ring AE; Ellis PA
    Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials.
    Jacquin JP; Jones S; Magné N; Chapelle C; Ellis P; Janni W; Mavroudis D; Martín M; Laporte S
    Breast Cancer Res Treat; 2012 Aug; 134(3):903-13. PubMed ID: 22270929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G; Loibl S; Maisch A; Untch M
    Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-based chemotherapy in metastatic breast cancer: current status.
    Decatris MP; Sundar S; O'Byrne KJ
    Cancer Treat Rev; 2004 Feb; 30(1):53-81. PubMed ID: 14766126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
    Herceg D; Vrbanec D
    Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
    Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
    Bria E; Nistico C; Cuppone F; Carlini P; Ciccarese M; Milella M; Natoli G; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2006 Jun; 106(11):2337-44. PubMed ID: 16649217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.